Actinium’s prostate cancer therapy shows efficacy over competitors

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) presented new preclinical data for its prostate cancer candidate ATNM-400 at the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans. The data shows ATNM-400, which uses the alpha-particle emitter Actinium -225, demonstrated superior cancer cell killing compared to Xtandi (enzalutamide) and greater efficacy than both Pluvicto (177Lu-PSMA-617) and Ac-225-PSMA-617 in laboratory and animal models. According to the company’s statement, ATNM-400 targets a non-PSMA receptor that is implicated in prostate cancer progression and therapeutic resistance. The target protein continues to be expressed after treatment with androgen receptor inhibitors and PSMA radiotherapy. Key findings showed ATNM-400 killed Xtandi-resistant prostate cancer cells that remained after Xtandi treatment. The therapy also demonstrated more effective tumor growth inhibition compared to both Pluvicto and 225Ac-PSMA-617 at t...